by | Jan 14, 2025 | Uncategorized
Source: CureToday articles Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma. Read More
by | Jan 9, 2025 | Uncategorized
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.“Combination therapy with teclistamab plus talquetamab showed encouraging antitumor...
by | Jan 7, 2025 | Uncategorized
Source: CureToday articles 2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk. Read More
by | Jan 2, 2025 | Uncategorized
SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.Anitocabtagene autoleucel (Arcellx Inc. and Kite Pharma/Gilead...
by | Dec 21, 2024 | Uncategorized
Source: CureToday articles Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination. Read More
by | Dec 17, 2024 | Uncategorized
Source: CureToday articles Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®. Read More